Role of an early second-look laparotomy in ovarian cancer.

[1]  S. Lippman,et al.  Second‐look laparotomy in epithelial ovarian carcinoma. Prognostic factors associated with survival duration , 1988, Cancer.

[2]  N. Colombo,et al.  A reassessment of the role of second-look laparotomy in advanced ovarian cancer. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Young.  A second look at second-look laparotomy. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. J. Webb,et al.  Second-look laparotomy--clinical correlations. , 1987, Gynecologic oncology.

[5]  R. J. Aukett,et al.  The role of second‐look laparotomy in the management of patients with Stage II, III and IV ovarian cancers following chemotherapy with cisplatin, adriamycin and cyclophosphamide , 1986 .

[6]  R. Bast,et al.  CA 125 serum levels correlated with second-look operations among ovarian cancer patients. , 1986, Obstetrics and gynecology.

[7]  P. Chollet,et al.  Second‐look laparotomy in managing epithelial ovarian carcinoma , 1986, Cancer.

[8]  J. Nisker,et al.  CA 125 surveillance and second-look laparotomy in ovarian carcinoma. , 1986, American journal of obstetrics and gynecology.

[9]  N. Teng,et al.  A critical reassessment of second‐look laparotomy in epithelial ovarian carcinoma , 1986, Cancer.

[10]  N. Sneige,et al.  Microscopic disease at second‐look laparotomy in advanced ovarian cancer , 1985, Cancer.

[11]  S. Vogl,et al.  “Second‐effort” surgical resection for bulky ovarian cancer , 1984, Cancer.

[12]  N. Hacker,et al.  Second-look laparotomy in stage III epithelial ovarian cancer: clinical variables associated with disease status. , 1984, Obstetrics and gynecology.

[13]  N. Mulder,et al.  Effective high-dose chemotherapy with autologous bone marrow infusion in resistant ovarian cancer. , 1984, Gynecologic oncology.

[14]  P. Saigo,et al.  A review of second-look laparotomy for ovarian cancer. , 1986, Gynecologic oncology.